Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed written consent given for three immunizations with MenBVac and five blood tests~* Between the ages of 18 and 55 years inclusive at recruitment~Exclusion Criteria:~* Previous history of bacteriologically confirmed meningococcal disease~* History of clinically significant allergic sensitivity to any vaccine received in the past~* Immunodeficiency~* Any other acute or chronic systemic illness or dependence or abuse of drugs or alcohol~* Language difficulties sufficient to preclude adequate comprehension of the study information~* Possibility of pregnancy~* Receipt of any other vaccine in the previous 4 weeks~* Receipt of any group B vaccine in the past~* Current participation in any other clinical trial~* Generalized acute systemic illness and/or temp \>38C on day of vaccination deferral

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).